Beloranib
Sources
registry, as of 2011-12-30Stale
https://clinicaltrials.gov/study/NCT01028261
Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers. Overall status COMPLETED. Phases PHASE1. Lead sponsor Zafgen, Inc.. Enrollment 31. Conditions Obesity. The purpose of this study is to assess whether multiple doses of ZGN-433 is safe and well tolerated in obese female subjects. The study will also provide information on how much ZGN-433 gets into the blood, how long does it stay in the body, and how it affects other biological ma
ClinicalTrials.gov NCT01028261 protocol and results modules
registry, as of 2016-07-14Stale
https://clinicaltrials.gov/study/NCT01666691
An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor Zafgen, Inc.. Enrollment 160. Conditions Obesity. The purpose of this study is to evaluate weight reduction, safety and pharmacokinetics for certain doses of beloranib (ZGN-440 for injectable suspension) administered as twice-weekly subcutaneous injections for 12 weeks.
ClinicalTrials.gov NCT01666691 protocol and results modules
registry, as of 2016-07-18Stale
https://clinicaltrials.gov/study/NCT02063295
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury. Overall status COMPLETED. Phases PHASE2. Lead sponsor Zafgen, Inc.. Enrollment 14. Conditions Obesity; Over-weight; Hypothalamic Injury; Craniopharyngioma. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of beloranib in obese subjects with hypothalamic injury.
ClinicalTrials.gov NCT02063295 protocol and results modules
registry, as of 2017-01-26Stale
https://clinicaltrials.gov/study/NCT02179151
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome. Overall status TERMINATED. Phases PHASE3. Lead sponsor Zafgen, Inc.. Enrollment 108. Conditions Prader-Willi Syndrome; Obesity. The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adolescent and adult subjects with Prader-Willi Syndrome.
ClinicalTrials.gov NCT02179151 protocol and results modules
registry, as of 2016-07-18Stale
https://clinicaltrials.gov/study/NCT01818921
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome. Overall status COMPLETED. Phases PHASE2. Lead sponsor Zafgen, Inc.. Enrollment 17. Conditions Obesity; Over-weight; Prader-Willi Syndrome. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics for certain doses of beloranib in obese subjects with Prader-Willi Syndrome.
ClinicalTrials.gov NCT01818921 protocol and results modules
registry, as of 2011-12-30Stale
https://clinicaltrials.gov/study/NCT01372761
Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers. Overall status COMPLETED. Phases PHASE1. Lead sponsor Zafgen, Inc.. Enrollment 25. Conditions Obesity. The purpose of this study is to assess whether multiple doses of ZGN-433 are safe and effective.
ClinicalTrials.gov NCT01372761 protocol and results modules
publication, as of 2018-07-20Stale
https://pubmed.ncbi.nlm.nih.gov/28556449/
The bestPWS clinical trial assessed the efficacy, safety and tolerability of the methionine aminopeptidase 2 (MetAP2) inhibitor, beloranib. Participants with PWS (12-65 years old) were randomly assigned (1:1:1) to biweekly placebo, 1.8 mg beloranib or 2.4 mg beloranib injection for 26 weeks at 15 US sites. Co-primary
PMID 28556449